Literature DB >> 3430952

Solute transport in continuous hemodialysis: a new treatment for acute renal failure.

M H Sigler1, B P Teehan.   

Abstract

A pumpless dialysis technique which combines continuous convection and diffusion was studied in 15 critically ill acute renal failure patients. Fluid identical in composition and purity to that used in peritoneal dialysis was continuously circulated (single-pass) at 16.6 cc/min through the dialysis compartment of a 0.43 m2 flat plate PAN membrane dialyzer. Whole blood clearances for urea, creatinine and phosphate averaged 25.3 +/- 4.4 cc/min, 24.1 +/- 5.5 cc/min and 21.3 +/- 5.6 cc/min, respectively. Over the range of blood flows studied (50 to 190 cc/min) clearances of these solutes were independent of blood flow rate but rather were determined by both dialysate flow rate and ultrafiltration rate. In contrast net fluxes of calcium and sodium were correlated only with ultrafiltration rate. Bicarbonate loss was 0.52 +/- 0.11 mEq/min; K+ balance varied with dialysate K+; glucose uptake from dialysate was 107 +/- 24.0 mg/min. In fresh non-clotting dialyzers, mean ultrafiltration rate was 8.1 cc/min. At QBi of 70 to 190 cc/min, dialysate and blood solute equilibrate yielding a total clearance equal to the dialysate outflow, or 25 cc/min, that is, the sum of dialysate flow rate plus ultrafiltration rate. In comparison to currently used continuous arteriovenous hemofiltration (CAVH), the exceptionally-high solute clearances obtained with continuous hemodialysis constitute a significant improvement in continuous renal replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3430952     DOI: 10.1038/ki.1987.245

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

1.  Continuous arteriovenous haemodialysis during emergency hepatic retransplantation: two case reports.

Authors:  F Salord; M P Bailly; P Gaussorgues; S Workineh; M Pouyet; D Robert
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 2.  Pharmacokinetics of continuous renal replacement therapy.

Authors:  M Schetz; P Ferdinande; G Van den Berghe; C Verwaest; P Lauwers
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

Review 3.  Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients.

Authors:  T A Golper; W M Bennett
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

4.  Continuous arteriovenous haemodialysis.

Authors:  E A Brown; W Kox
Journal:  BMJ       Date:  1988-07-23

5.  Intermittent hemodialysis in critically ill patients with multiple organ dysfunction syndrome is associated with intestinal intramucosal acidosis.

Authors:  G Van der Schueren; M Diltoer; M Laureys; L Huyghens
Journal:  Intensive Care Med       Date:  1996-08       Impact factor: 17.440

6.  Continuous arteriovenous hemodialysis: an alternative therapy for acute renal failure associated with critical illness.

Authors:  R T Gibney; D E Stollery; R E Lefebvre; C J Sharun; P Chan
Journal:  CMAJ       Date:  1988-11-01       Impact factor: 8.262

7.  Continuous arteriovenous haemodialysis and haemofiltration in intensive care acute renal failure patients.

Authors:  A A Alarabi; A Taube; B G Danielson; B Wikström
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

8.  Continuous arterio-venous haemodiafiltration: hydraulic and diffusive permeability index of an AN-69 capillary haemofilter.

Authors:  E Akcahuseyin; W A van Duyl; H H Vincent; M C Vos; M A Schalekamp
Journal:  Med Biol Eng Comput       Date:  1998-01       Impact factor: 2.602

9.  Treatment of acute renal failure in an infant by continuous arteriovenous hemodialysis.

Authors:  F K Assadi
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

Review 10.  Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view.

Authors:  M Schetz; P M Lauwers; P Ferdinande
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.